This provides the opportunity for exploring rOPG’s potential as a dual-action therapeutic in the treatment of breast cancer, where its mechanism of action involves blocking RANKL to reduce bone metastasis in breast cancer while also reducing the progression of breast cancer through targeting the β-catenin/wnt pathway, inducing inhibition of cancer stem cell signaling. This evidence concerns the gene TNFSF11 and breast carcinoma.